Research ArticleClinical Investigation
Nuclear Localization of 111In After Intravenous Injection of [111In-DTPA-D-Phe1]-Octreotide in Patients with Neuroendocrine Tumors
Eva Tiensuu Janson, Jan-Erik Westlin, Ulf Öhrvall, Kjell Öberg and Agneta Lukinius
Journal of Nuclear Medicine September 2000, 41 (9) 1514-1518;
Eva Tiensuu Janson
Jan-Erik Westlin
Ulf Öhrvall
Kjell Öberg


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Nuclear Localization of 111In After Intravenous Injection of [111In-DTPA-D-Phe1]-Octreotide in Patients with Neuroendocrine Tumors
Eva Tiensuu Janson, Jan-Erik Westlin, Ulf Öhrvall, Kjell Öberg, Agneta Lukinius
Journal of Nuclear Medicine Sep 2000, 41 (9) 1514-1518;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Molecular mechanisms of somatostatin receptor trafficking
- Auger Electrons: Lethal, Low Energy, and Coming Soon to a Tumor Cell Nucleus Near You
- Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
- Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for Targeted Radiotherapy of Cancer
- Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves' Disease
- Cancer Therapy with Auger Electrons: Are We Almost There?
- Peptide Receptor Radionuclide Therapy In Vitro Using [111In-DTPA0]Octreotide
- Somatostatin Receptor Gene Expression in Human Ocular Tissues: RT-PCR and Immunohistochemical Study
- Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with 111Indium, 67Gallium, or 90Yttrium